8-K current report · filed Nov 12, 2026

4D Molecular Therapeutics, Inc. (FDMT) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1FDMT overview

Short answer

4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter 2026 financial results announced for the period ended September 30, 2026.

4D Molecular Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter 2026 financial results announced for the period ended September 30, 2026
  • Press release includes operational highlights and expected upcoming milestones
  • Exhibit 99.1 contains the detailed financial results and management update

Item EX-99.1 · Exhibit EX-99.1

  • 4FRONT-1 and 4FRONT-2 randomized 523 and 531 patients, with wet AMD topline data expected Q2 2027 and H2 2027
  • 4SIGHT Phase 3 initiated in DME with 514 patients, testing 4D-150 against aflibercept on vision and injection-burden reduction
  • Cash $375.0M, down from $514.0M at December 31, 2025, expected to fund operations into H2 2028 including Otsuka payments
  • Q3 revenue $4.1M versus $0.1M, driven by Otsuka cost sharing and reimbursement
  • Q3 net loss $78.1M versus $56.9M, while R&D rose to $69.8M from $49.4M as Phase 3 execution accelerated

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other 4D Molecular Therapeutics, Inc. 8-K filings

Get the next FDMT 8-K as it lands

Follow FDMT for push alerts, or ask the research agent what this filing means.